Peptide Vaccines for Cancer

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1986 • 1,723 citations

Model Predicting Survival in Stage I Melanoma Based on Tumor Progression

1989 • 1,235 citations

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

1995 • 1,147 citations

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1999 • 1,131 citations

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

1994 • 1,108 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1994 • 934 citations

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 • 921 citations

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

1994 • 850 citations

Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 • 841 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

1994 • 771 citations

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

1998 • 728 citations

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

1992 • 694 citations

Cytotoxic T cells recognize fragments of the influenza nucleoprotein

1985 • 669 citations

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

1994 • 584 citations

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

1996 • 566 citations

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

1996 • 542 citations

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

1998 • 534 citations

Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

1989 • 511 citations

High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

1999 • 497 citations

Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues

1998 • 487 citations

Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

1994 • 421 citations

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

1995 • 416 citations

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

1996 • 416 citations

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

1995 • 387 citations

Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.

1993 • 385 citations

Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.

1993 • 344 citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

1999 • 339 citations

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

1995 • 324 citations

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo

1996 • 308 citations

Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies

1999 • 301 citations

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

1995 • 296 citations

Vitiligo in patients with metastatic melanoma: A good prognostic sign

1983 • 292 citations

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

1997 • 286 citations

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1996 • 285 citations

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

1995 • 282 citations

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo

1996 • 274 citations

Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

1996 • 272 citations

Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.

1992 • 269 citations

A Phase I Trial of a Synthetic Mucin Peptide Vaccine

1996 • 268 citations

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

1996 • 261 citations

H—2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide

1986 • 252 citations

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens

1996 • 250 citations

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial

1999 • 231 citations

Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.

1989 • 227 citations

Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.

1989 • 223 citations

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

1999 • 223 citations

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

1998 • 220 citations

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

1996 • 215 citations

Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.

1996 • 209 citations

A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames

1998 • 208 citations

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

1990 • 206 citations

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

1995 • 192 citations

Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine

1999 • 188 citations

Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

1997 • 187 citations

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).

1996 • 182 citations

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

1998 • 176 citations

Prognostic significance of hypopigmentation in malignant melanoma

1987 • 176 citations

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

1997 • 176 citations

Molecular characterization of the melanocyte lineage-specific antigen gp100.

1994 • 169 citations

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1997 • 163 citations

Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.

1993 • 140 citations

Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ Lesions

1996 • 131 citations

A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk Melanoma

1999 • 128 citations

Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line

1995 • 128 citations

Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors

1996 • 127 citations

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

1995 • 121 citations

A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors

1999 • 117 citations

Biologic Behavior of Thin Malignant Melanomas With Regressive Changes

1983 • 111 citations

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

1996 • 106 citations

Specific Identification of an Authentic Clone for Mammalian Tyrosinase

1989 • 106 citations

Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.

1989 • 104 citations

T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.

1993 • 98 citations

Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients

1999 • 95 citations

Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.

1995 • 94 citations

Comparative Analysis of the In Vivo Expression of Tyrosinase, MART-1/Melan-A, and gp100 in Metastatic Melanoma Lesions: Implications for Immunotherapy

1998 • 94 citations

Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

1996 • 85 citations

Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.

1995 • 81 citations

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

1996 • 80 citations

Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12

1999 • 68 citations

Overlapping peptides of melanocyte differentiation antigen melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1

1998 • 62 citations

Differential Expression of MART-1 in Primary and Metastatic Melanoma Lesions

1997 • 58 citations

High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen-specific vaccination strategies

1998 • 57 citations

Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy

1998 • 56 citations

Immunocytochemical Detection of MART-1 in Fresh and Paraffin-Embedded Malignant Melanomas

1997 • 56 citations

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.

1996 • 53 citations

Identification of GP100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primaryin vitro immunization with peptide-pulsed dendritic cells

1998 • 51 citations

Sequential chemoimmunotherapy for metastatic melanoma.

1991 • 42 citations

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.

1996 • 40 citations

Biology, biochemistry and immunology of carcinoma-associated mucins

1997 • 39 citations

A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis

1997 • 35 citations

Correlative Study of Human Papillomavirus DNA, Histopathology, and Morphometry in Cervical Condyloma and Intraepithelial Neoplasia

1988 • 34 citations